Beigene (ONC) Competitors

Beigene (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.

Does the MarketBeat Community believe in ONC or GSK?

GSK received 812 more outperform votes than Beigene when rated by MarketBeat users. However, 80.00% of users gave Beigene an outperform vote while only 57.10% of users gave GSK an outperform vote.

Company	Underperform	Outperform
Beigene	Outperform Votes 12 80.00%	Underperform Votes 3 20.00%
GSK	Outperform Votes 824 57.10%	Underperform Votes 619 42.90%

Which has preferable valuation and earnings, ONC or GSK?

GSK has higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beigene	$4.18B	5.73	-$881.71M	-$3.72	-64.90
GSK	$31.53B	2.53	$3.29B	$1.94	19.95

Is ONC or GSK more profitable?

GSK has a net margin of 8.13% compared to Beigene's net margin of -25.94%. GSK's return on equity of 48.59% beat Beigene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
GSK	8.13%	48.59%	11.11%

Which has more risk and volatility, ONC or GSK?

Beigene has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Does the media refer more to ONC or GSK?

In the previous week, GSK had 25 more articles in the media than Beigene. MarketBeat recorded 28 mentions for GSK and 3 mentions for Beigene. GSK's average media sentiment score of 1.19 beat Beigene's score of 0.24 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beigene	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	21 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ONC or GSK?

Beigene presently has a consensus price target of $319.00, indicating a potential upside of 32.13%. GSK has a consensus price target of $40.58, indicating a potential upside of 4.88%. Given Beigene's stronger consensus rating and higher probable upside, equities analysts plainly believe Beigene is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.42

Do institutionals & insiders have more ownership in ONC or GSK?

48.5% of Beigene shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 6.6% of Beigene shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

GSK beats Beigene on 13 of the 19 factors compared between the two stocks.